MiNK Therapeutics (NASDAQ:INKT) CEO Jennifer Buell Sells 6,938 Shares of Company Stock

MiNK Therapeutics, Inc. (NASDAQ:INKT) CEO Jennifer Buell sold 6,938 shares of MiNK Therapeutics stock in a transaction on Monday, October 12th. The stock was sold at an average price of $10.56, for a total value of $73,265.28. Following the completion of the sale, the chief executive officer directly owned 74,195 shares of the company’s stock, valued at approximately $783,499.20. The trade was a 8.55% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

MiNK Therapeutics Stock Performance

Shares of INKT stock traded up $0.03 during mid-day trading on Wednesday, hitting $10.26. The company’s stock had a trading volume of 5,084 shares, compared to its average volume of 109,054. MiNK Therapeutics, Inc. has a 52-week low of $8.48 and a 52-week high of $16.93. The business has a 50-day moving average price of $11.62 and a 200 day moving average price of $11.47. The stock has a market cap of $52.33 million, a price-to-earnings ratio of -4.27 and a beta of 0.47.

MiNK Therapeutics (NASDAQ:INKT) last announced its quarterly earnings results on Thursday, August 13th. The company reported ($0.62) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.02). Equities research analysts predict that MiNK Therapeutics, Inc. will post -1.93 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research firms have recently issued reports on INKT. Zacks Research downgraded MiNK Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, August 12th. Weiss Ratings reissued a “sell (d-)” rating on shares of MiNK Therapeutics in a report on Friday, October 2nd. One investment analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $35.00.

MiNK Therapeutics Company Profile

MiNK Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing cell therapies for cancer. The company’s research centers on invariant natural killer T (iNKT) cells, an immune cell type that can recognize and attack tumor cells while helping activate broader immune responses.

MiNK’s lead product candidate, agenT-797, is an allogeneic, or donor-derived, iNKT cell therapy designed for use as an off-the-shelf treatment. The candidate has been evaluated in clinical studies involving patients with advanced cancers, including solid tumors and hematologic malignancies, both as a standalone therapy and in combination with other cancer treatments.

The company is also advancing its broader iNKT cell therapy platform and additional product candidates intended to address challenges such as tumor immunosuppression and limited immune-cell activity within solid tumors.